Patents by Inventor Alexander Federation

Alexander Federation has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolation and characterization of the nuclear proteome
    Patent number: 12276667
    Abstract: Disclosed herein are methods for solubilizing and isolating nuclear proteins from cells.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: April 15, 2025
    Assignee: Altius Institute for Biomedical Sciences
    Inventors: Alexander Federation, John Stamatoyannopoulos
  • CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF
    Publication number: 20250034126
    Abstract: Provided herein are compounds useful as inhibitors of CBX. Also described are pharmaceutical compositions and medical uses of these compounds.
    Type: Application
    Filed: September 26, 2024
    Publication date: January 30, 2025
    Inventors: James E. Bradner, Jun Qi, Alexander Federation, Zoe Jacobson, Anthony Varca
  • Chromobox protein inhibitors and uses thereof
    Patent number: 12129248
    Abstract: Provided herein are compounds useful as inhibitors of CBX. Also described are pharmaceutical compositions and medical uses of these compounds.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: October 29, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Jun Qi, Alexander Federation, Zoe Jacobson, Anthony Varca
  • CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF
    Publication number: 20200024267
    Abstract: Provided herein are compounds useful as inhibitors of CBX. Also described are pharmaceutical compositions and medical uses of these compounds.
    Type: Application
    Filed: September 25, 2017
    Publication date: January 23, 2020
    Inventors: James Bradner, Jun Qi, Alexander Federation, Zoe Jacobson, Anthony Varca
  • DOT1L probes
    Patent number: 9535067
    Abstract: The present invention relates to compound that bind Histone H3-lysine79 (H3K79) methyl transferase (DOTIL). The disclosed compounds are useful as for assessing the activity of DOTIL and for identifying inhibitors of DOTIL. Described herein are probes useful for both assessing the activity of DOTIL and identifying inhibitors of DOTIL. These probes can be used in various assays, including Amplified Luminescent Proximity Homogeneous Assays (“ALPHA” assays), Differential Scanning Fluorimetry (DFS) Assay, and Fluorescence Polarization (FP) assays used for high-throughput screening (HTS) for small molecule drug discovery. The compounds can also be used as a pull down agent for target identification.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: January 3, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Alexander Federation, Jun Qi
  • DOT1L inhibitors
    Patent number: 9458165
    Abstract: Provided herein are inhibitors of DOT1L of formula (I) useful for treating diseases or disorders associated with DOT1L: in which R1 is defined in the specification. An exemplary DOT1L inhibitor provided herein exhibits a biological half-life of 12.6 h. Methods for treating diseases associated with DOT1L are also provided.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: October 4, 2016
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Jun Qi, Alexander Federation
  • DOT1L PROBES
    Publication number: 20160146817
    Abstract: The present invention relates to compound that bind Histone H3-lysine79 (H3K79) methyl transferase (DOTIL). The disclosed compounds are useful as for assessing the activity of DOTIL and for identifying inhibitors of DOTIL. Described herein are probes useful for both assessing the activity of DOTIL and identifying inhibitors of DOTIL. These probes can be used in various assays, including Amplified Luminescent Proximity Homogeneous Assays (“ALPHA” assays), Differential Scanning Fluorimetry (DFS) Assay, and Fluorescence Polarization (FP) assays used for high-throughput screening (HTS) for small molecule drug discovery. The compounds can also be used as a pull down agent for target identification.
    Type: Application
    Filed: July 28, 2014
    Publication date: May 26, 2016
    Inventors: James E. Bradner, Alexander Federation, Jun Qi
  • DOT1L Inhibitors
    Publication number: 20160060269
    Abstract: Provided herein are inhibitors of DOT1L useful for treating diseases or disorders associated with DOT1L. An exemplary DOT1L inhibitor provided herein exhibits a biological half-life of 12.6 h. Methods for treating diseases associated with DOT1L are also provided.
    Type: Application
    Filed: August 27, 2015
    Publication date: March 3, 2016
    Inventors: James E. Bradner, Jun Qi, Alexander Federation